AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27301417 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol/glycopyrronium (IND/GLY) 110/50 μg once daily (OD)
Number of subjects: 194
Study 27301417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 194
Study 24526247 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen/tramadol 325 mg/37.5 mg per capsule, maximum acetaminophen 1,950 mg and tramadol 225 mg per day; treatment duration 2 weeks.
Number of subjects: 50
Study 24526247 — intervention group
Group type: COMPARATOR
Intervention: Placebo, titrated identically to treatment.
Number of subjects: 50
Study 22399127 — intervention group
Group type: EXPERIMENTAL
Intervention: Spring-loaded syringe (n=20)
Number of subjects: 60
Study 22399127 — intervention group
Group type: COMPARATOR
Intervention: Loss-of-resistance syringe (n=20)
Number of subjects: 60
Study 22399127 — intervention group
Group type: COMPARATOR
Intervention: Hanging drop technique (n=20)
Number of subjects: 60
Study 22399127 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60
Study 19460715 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy combined with trastuzumab
Number of subjects: 3
Study 19460715 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy only
Number of subjects: 3
Study 17627399 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment regimens
Number of subjects: 5017
Study 15867582 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (0.05 mg/kg per day)
Number of subjects: 7
Study 15867582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 12062539 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aspirin (1000 mg bolus given 1 day before angioplasty)
Number of subjects: 51
Study 12062539 — intervention group
Group type: COMPARATOR
Intervention: Low-dose aspirin (100 mg/day only)
Number of subjects: 51
Study 12062539 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aspirin intervention)
Number of subjects: 51
Study 9828247 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose epinephrine (5 mg each, up to 15 doses)
Number of subjects: 3327
Study 9828247 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose epinephrine (1 mg each, up to 15 doses)
Number of subjects: 3327
Study 10220206 — intervention group
Group type: EXPERIMENTAL
Intervention: Lispro + NPH (5 min before breakfast and lunch, lispro before dinner, NPH at bedtime)
Number of subjects: 25
Study 10220206 — intervention group
Group type: EXPERIMENTAL
Intervention: Lispro + NPH
Number of subjects: 25
Study 10220206 — intervention group
Group type: COMPARATOR
Intervention: Soluble insulin + NPH (20‐30 min before each meal and NPH at bedtime)
Number of subjects: 25
Study 1703916 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy followed by definitive radiation therapy (RT) - 70 Gy to involved areas and 50 Gy to uninvolved neck at 2 Gy/fraction, five fractions per week.
Number of subjects: 116
Study 1703916 — intervention group
Group type: COMPARATOR
Intervention: Alternating chemotherapy and radiation therapy (RT) - 60 Gy to involved areas and 50 Gy to uninvolved neck in three courses of 20 Gy each, 2 Gy/fraction, ten fractions/2 weeks alternated with four courses of chemotherapy.
Number of subjects: 116
Study 6305387 — intervention group
Group type: EXPERIMENTAL
Intervention: benoxaprofen
Number of subjects: 24
Study 6305387 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 24
Study 30557623 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 weeks of programmed vigorous-intensity exercise
Number of subjects: 150
Study 30557623 — intervention group
Group type: COMPARATOR
Intervention: 15 weeks of programmed low-intensity exercise
Number of subjects: 150
Study 29304531 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary nitrate supplement (SiS nitrate gel)
Number of subjects: 20
Study 29304531 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel therapy
Number of subjects: 20
Study 25261789 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine content instructions (e‐cigarette contained nicotine)
Number of subjects: 21
Study 25261789 — intervention group
Group type: COMPARATOR
Intervention: Nicotine content instructions (e‐cigarette was nicotine-free)
Number of subjects: 21
Study 23290154 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline plus SFC (200 mg theophylline plus 50/250 μg SFC)
Number of subjects: 325
Study 23290154 — intervention group
Group type: COMPARATOR
Intervention: SFC plus placebo (placebo tablet plus 50/250 μg SFC)
Number of subjects: 325
Study 23290154 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline plus SFC
Number of subjects: 325
Study 23290154 — intervention group
Group type: COMPARATOR
Intervention: SFC plus placebo
Number of subjects: 325
Study 21906278 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician-directed, Internet-delivered intervention for improving care
Number of subjects: 957
Study 21906278 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured recruitment with physician recruiters and dedicated IRB manager
Number of subjects: 957
Study 18226936 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and advice
Number of subjects: 0
Study 18226936 — intervention group
Group type: COMPARATOR
Intervention: Advice alone
Number of subjects: 0
Study 16816224 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 554
Study 16816224 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 554
Study 16816224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 554
Study 12535199 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial sunscreen (SPF 15)
Number of subjects: 119
Study 10674611 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled closure
Number of subjects: 141
Study 10674611 — intervention group
Group type: COMPARATOR
Intervention: Sutured closure
Number of subjects: 141
Study 10674611 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 141
Study 8790022 — intervention group
Group type: EXPERIMENTAL
Intervention: Reteplase (10 plus 10 megaunits double bolus)
Number of subjects: 324
Study 8790022 — intervention group
Group type: COMPARATOR
Intervention: Alteplase (front-loaded)
Number of subjects: 324
Study 1297907 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 36
Study 1297907 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 6494811 — intervention group
Group type: EXPERIMENTAL
Intervention: Netilmicin + Tinidazole (N + T)
Number of subjects: 41
Study 6494811 — intervention group
Group type: COMPARATOR
Intervention: Netilmicin + Clindamycin (N + C)
Number of subjects: 41
Study 31605923 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF MDI) 320/18/9.6 μg
Number of subjects: 8572
Study 31605923 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF MDI) 160/18/9.6 μg
Number of subjects: 8572
Study 31605923 — intervention group
Group type: COMPARATOR
Intervention: Glycopyrrolate/formoterol fumarate (GFF) MDI 18/9.6 μg
Number of subjects: 8572
Study 31605923 — intervention group
Group type: COMPARATOR
Intervention: Budesonide/formoterol fumarate (BFF) MDI 320/9.6 μg
Number of subjects: 8572
Study 29284320 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous peramivir
Number of subjects: 123
Study 29284320 — intervention group
Group type: COMPARATOR
Intervention: Oral oseltamivir
Number of subjects: 123
Study 29284320 — intervention group
Group type: COMPARATOR
Intervention: Inhaled zanamivir
Number of subjects: 123
Study 29284320 — intervention group
Group type: COMPARATOR
Intervention: Inhaled laninamivir
Number of subjects: 123
Study 26655020 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogenated vegetable oils (HVOs) consumption
Number of subjects: 1582
Study 26655020 — intervention group
Group type: EXPERIMENTAL
Intervention: Butter consumption
Number of subjects: 1582
Study 26655020 — intervention group
Group type: COMPARATOR
Intervention: Non-hydrogenated vegetable oils (non-HVOs) consumption
Number of subjects: 1582
Study 26655020 — intervention group
Group type: COMPARATOR
Intervention: Non-consumption of butter
Number of subjects: 1582
Study 23877621 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin maintenance dosing algorithm
Number of subjects: 537
Study 23877621 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 537
Study 22822010 — intervention group
Group type: EXPERIMENTAL
Intervention: Buttonhole needling
Number of subjects: 140
Study 22822010 — intervention group
Group type: COMPARATOR
Intervention: Standard needling
Number of subjects: 140
Study 20042648 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test (OGTT)
Number of subjects: 24
Study 20042648 — intervention group
Group type: COMPARATOR
Intervention: Fasting regimen
Number of subjects: 24
Study 17108011 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophilic acrylic intraocular lens (IOL)
Number of subjects: 53
Study 17108011 — intervention group
Group type: COMPARATOR
Intervention: Hydrophobic acrylic intraocular lens (IOL)
Number of subjects: 53
Study 15860711 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength exercise
Number of subjects: 15
Study 15860711 — intervention group
Group type: COMPARATOR
Intervention: High intensity exercise (80% of maximum exercise capacity)
Number of subjects: 15
Study 15860711 — intervention group
Group type: COMPARATOR
Intervention: Interval exercise
Number of subjects: 15
Study 12004217 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonic J-pouch
Number of subjects: 74
Study 12004217 — intervention group
Group type: COMPARATOR
Intervention: Coloanal anastomosis
Number of subjects: 74
Study 9547085 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual delay of 0% of cycle duration
Number of subjects: 5
Study 9547085 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual delay of 100% of cycle duration
Number of subjects: 5
Study 9547085 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual delay of about 50% of cycle duration
Number of subjects: 5
Study 9547085 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual delays up to 50% of target cycle duration
Number of subjects: 5
Study 9547085 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual delays larger than 50% of target cycle duration
Number of subjects: 5
Study 9547085 — intervention group
Group type: EXPERIMENTAL
Intervention: Different visual delays ranging from 0 to 120% of cycle duration
Number of subjects: 5
Study 9894360 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinyl propionate cream
Number of subjects: 80
Study 9894360 — intervention group
Group type: COMPARATOR
Intervention: Placebo preparation
Number of subjects: 80
Study 2653717 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime (CTX) 200 mg/kg/day
Number of subjects: 50
Study 2653717 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin (AMP) and chloramphenicol succinate (CAPS)
Number of subjects: 50
Study 814180 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone valerate
Number of subjects: 20
Study 814180 — intervention group
Group type: COMPARATOR
Intervention: Sodium cromoglycate
Number of subjects: 20
Study 30819077 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AE)
Number of subjects: 55
Study 30819077 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Exercise (RE)
Number of subjects: 55
Study 30819077 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 55
Study 27324833 — intervention group
Group type: COMPARATOR
Intervention: Device-only feedback (DFB)
Number of subjects: 63
Study 27324833 — intervention group
Group type: COMPARATOR
Intervention: Verbal feedback from a qualified dental instructor (IFB)
Number of subjects: 63
Study 27324833 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of instructor and device feedback (IDFB)
Number of subjects: 63
Study 25938855 — intervention group
Group type: EXPERIMENTAL
Intervention: MIRRORS (Mindfulness Intervention for Rehabilitation and Recovery in Schizophrenia)
Number of subjects: 34
Study 25938855 — intervention group
Group type: COMPARATOR
Intervention: Intensive Support
Number of subjects: 34
Study 23478860 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support (CDS)
Number of subjects: 55779
Study 23478860 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance Feedback
Number of subjects: 55779
Study 23478860 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined CDS and Performance Feedback
Number of subjects: 55779
Study 23478860 — intervention group
Group type: COMPARATOR
Intervention: Non-CDS visits
Number of subjects: 55779
Study 21824799 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg/day of conjugated equine estrogens
Number of subjects: 23
Study 21824799 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 23
Study 19309184 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol Behavioral Couple Therapy (ABCT)
Number of subjects: 102
Study 19309184 — intervention group
Group type: COMPARATOR
Intervention: Alcohol Behavioral Individual Therapy (ABIT)
Number of subjects: 102
Study 19309184 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCT
Number of subjects: 102
Study 16886978 — intervention group
Group type: EXPERIMENTAL
Intervention: Rufinamide 200 mg/day
Number of subjects: 189
Study 16886978 — intervention group
Group type: EXPERIMENTAL
Intervention: Rufinamide 400 mg/day
Number of subjects: 189
Study 16886978 — intervention group
Group type: EXPERIMENTAL
Intervention: Rufinamide 800 mg/day
Number of subjects: 189
Study 16886978 — intervention group
Group type: EXPERIMENTAL
Intervention: Rufinamide 1600 mg/day
Number of subjects: 189
Study 16886978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189
Study 15260911 — intervention group
Group type: EXPERIMENTAL
Intervention: rilmenidine 3 mg once daily
Number of subjects: 15
Study 11726259 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle ergometer
Number of subjects: 18
Study 11726259 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill
Number of subjects: 18
Study 11726259 — intervention group
Group type: EXPERIMENTAL
Intervention: Stairstepper
Number of subjects: 18
Study 11726259 — intervention group
Group type: EXPERIMENTAL
Intervention: All modes of exercise
Number of subjects: 18
Study 9159031 — intervention group
Group type: COMPARATOR
Intervention: Ulcerative colitis
Number of subjects: 0
Study 9159031 — intervention group
Group type: COMPARATOR
Intervention: Crohn's disease
Number of subjects: 0
Study 9159031 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between Crohn's disease and ulcerative colitis
Number of subjects: 0
Study 7895460 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin and Glibenclamide (MGL)
Number of subjects: 165
Study 7895460 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy (Metformin or Glibenclamide)
Number of subjects: 165
Study 7895460 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Metformin and Glibenclamide)
Number of subjects: 165
Study 7895460 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 165
Study 7895460 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 165
Study 2441013 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly group sessions with videotapes for diabetic persons with low literacy skills
Number of subjects: 120
Study 2441013 — intervention group
Group type: COMPARATOR
Intervention: Monthly group sessions without videotapes
Number of subjects: 120
Study 2441013 — intervention group
Group type: COMPARATOR
Intervention: No monthly sessions
Number of subjects: 120
Study 30144017 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 129
Study 30144017 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 129
Study 27245741 — intervention group
Group type: EXPERIMENTAL
Intervention: PPROM for ≥3 weeks
Number of subjects: 1305
Study 27245741 — intervention group
Group type: COMPARATOR
Intervention: PPROM for <3 weeks
Number of subjects: 1305
Study 25654961 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel matrix derivative (EMD; Emdogain)
Number of subjects: 30
Study 25654961 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF)
Number of subjects: 30
Study 25654961 — intervention group
Group type: COMPARATOR
Intervention: Both EMD and PRF
Number of subjects: 30
Study 22909093 — intervention group
Group type: EXPERIMENTAL
Intervention: Information provided by prescribers
Number of subjects: 12
Study 22909093 — intervention group
Group type: COMPARATOR
Intervention: Lack of information or support
Number of subjects: 12
Study 20132153 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg
Number of subjects: 52
Study 20132153 — intervention group
Group type: COMPARATOR
Intervention: Pantoprazole 40 mg
Number of subjects: 52
Study 19077067 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative management with medium chain triglyceride-enriched diet or total parenteral nutrition in combination with adequate drainage of pleural fluid
Number of subjects: 0
Study 19077067 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin or octreotide therapy
Number of subjects: 0
Study 19077067 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention
Number of subjects: 0
Study 19077067 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm for therapeutic approach to management
Number of subjects: 0
Study 15673645 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamphlet intervention
Number of subjects: 128
Study 15673645 — intervention group
Group type: EXPERIMENTAL
Intervention: Video intervention
Number of subjects: 128
Study 15673645 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamphlet plus video intervention
Number of subjects: 128
Study 15673645 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 128
Study 12093420 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive health visits
Number of subjects: 1002
Study 12093420 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician's recommendation for FSIG or FOBT cards
Number of subjects: 1002
Study 12093420 — intervention group
Group type: COMPARATOR
Intervention: Insurance status
Number of subjects: 1002
Study 12093420 — intervention group
Group type: COMPARATOR
Intervention: Type of insurance
Number of subjects: 1002
Study 10528370 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human bone morphogenetic protein 2 with Type I collagen carrier
Number of subjects: 6
Study 10528370 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human bone morphogenetic protein 2 with polylactic acid carrier
Number of subjects: 6
Study 10528370 — intervention group
Group type: COMPARATOR
Intervention: Collagen carrier alone (no recombinant human bone morphogenetic protein 2)
Number of subjects: 6
Study 10528370 — intervention group
Group type: COMPARATOR
Intervention: Autogenous rib graft alone
Number of subjects: 6
Study 10528370 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human bone morphogenetic protein 2 treatment groups
Number of subjects: 6
Study 10528370 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen carrier
Number of subjects: 6
Study 7727671 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime
Number of subjects: 28
Study 7727671 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 28
Study 2139285 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant yeast-derived hepatitis B vaccine (YDV) 20 micrograms, administered according to a 0, 1, 6 month schedule.
Number of subjects: 275
Study 507790 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin or Tobramycin
Number of subjects: 120
Study 507790 — intervention group
Group type: EXPERIMENTAL
Intervention: Ideal body weight for AMG dosage calculation
Number of subjects: 120
Study 507790 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG-induced nephrotoxicity
Number of subjects: 120
Study 507790 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak AMG serum concentrations
Number of subjects: 120
Study 507790 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum inhibitory levels of greater than or equal to 1:8
Number of subjects: 120
Study 507790 — intervention group
Group type: COMPARATOR
Intervention: Mortality between gentamicin and tobramycin
Number of subjects: 120
Study 31830753 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-site rTMS treatment
Number of subjects: 30
Study 31830753 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 30
Study 28711109 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 282
Study 28711109 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-Term Psychodynamic Supportive Psychotherapy (SPSP)
Number of subjects: 282
Study 25015237 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaching Boys Into Men (CBIM) program
Number of subjects: 176
Study 25015237 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 176
Study 23578592 — intervention group
Group type: EXPERIMENTAL
Intervention: CR Equipements SACH foot
Number of subjects: 15
Study 23578592 — intervention group
Group type: COMPARATOR
Intervention: SACH foot
Number of subjects: 15
Study 21323524 — intervention group
Group type: EXPERIMENTAL
Intervention: pegfilgrastim 6 mg on day +1
Number of subjects: 40
Study 21323524 — intervention group
Group type: COMPARATOR
Intervention: filgrastim (daily starting at median day +7)
Number of subjects: 40
Study 21323524 — intervention group
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Number of subjects: 40
Study 21323524 — intervention group
Group type: EXPERIMENTAL
Intervention: pegfilgrastim and filgrastim
Number of subjects: 40
Study 19369086 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (postoperatively)
Number of subjects: 21
Study 19369086 — intervention group
Group type: COMPARATOR
Intervention: No angiotensin converting enzyme inhibitor (control group)
Number of subjects: 21
Study 16496034 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone treatment
Number of subjects: 80
Study 16496034 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone treatment (adherent)
Number of subjects: 80
Study 16496034 — intervention group
Group type: COMPARATOR
Intervention: Methadone maintenance (control)
Number of subjects: 80